Centre Hospitalier Regional D'Angers
- Address
- 4 Rue Larrey, 49100 Angers, France
Cardiovascular and Vascular Medicine
The Centre Hospitalier Regional D'Angers is active in cardiovascular diseases and related circulatory phenomena, with studies focused on conditions such as acute myocardial infarction, deep vein thrombosis, pulmonary embolism, venous thromboembolism, and pulmonary hypertension. This research is largely aimed at improving prevention, diagnosis, and treatment effectiveness in common and high-risk vascular disorders.
- Evaluating new approaches for pulmonary hypertension and pulmonary hypertension associated with COPD
- Studying better strategies to prevent and manage venous thromboembolism and related clotting events
- Assessing treatment effectiveness in serious cardiovascular disease and acute vascular complications
These trials reflect a strong clinical focus on reducing complications and improving outcomes for patients with major vascular and heart-related diseases.
Respiratory and Critical Care Research
Research at this site also covers respiratory tract diseases and critical care, including COPD, pneumonia, progressive pulmonary fibrosis, interstitial lung disease, and respiratory distress syndrome in preterm babies. The trials are designed to test new therapies, improve supportive care, and understand which treatments best preserve lung function and survival.
- Testing therapies for COPD and severe respiratory failure in intensive care settings
- Evaluating treatments for progressive pulmonary fibrosis and other chronic lung diseases
- Improving care for preterm infants with breathing complications
Several studies also examine ways to improve hospital recovery, ventilator-free days, and comfort in critically ill patients.
Oncology and Hematology
Much of the clinical research here centers on neoplasms and hematologic diseases, especially non-small cell lung cancer, hepatocellular carcinoma, bladder cancer, myelodysplastic syndromes, multiple myeloma, acute myeloid leukemia, and lymphoma. The purpose of these trials is to evaluate new cancer treatments, refine personalized therapy, and improve long-term disease control.
- Testing immunotherapy and targeted treatment strategies for non-small cell lung cancer
- Studying personalized and adjuvant approaches in liver cancer, bladder cancer, and colon cancer
- Evaluating new options for blood cancers such as MDS, AML, myeloma, and lymphoma
The oncology portfolio includes both treatment intensification and treatment de-escalation studies, with a clear interest in matching therapy to disease biology.
Immunology, Autoimmune Disease, and Transplantation
This site is also involved in research on immune system diseases and transplant-related care, including immune thrombocytopenia, ANCA-associated vasculitis, kidney transplant, and haploidentical hematopoietic stem cell transplantation. The trials aim to improve immune control, reduce relapse, and make transplant outcomes safer and more durable.
- Assessing therapies for immune thrombocytopenia and vasculitis
- Studying infection prevention and immune protection after kidney transplant
- Improving outcomes after hematopoietic stem cell transplantation for blood cancers
These studies show a strong interest in balancing immune suppression with protection against relapse and infection.
Surgical, Diagnostic, and Perioperative Studies
Clinical trials at Centre Hospitalier Regional D'Angers also address diagnosis, therapeutics, and surgical procedures, with a focus on digestive cancer surgery, labor induction, rapid sequence induction, and postoperative recovery. These studies are intended to improve safety, guide treatment decisions, and optimize outcomes around surgery and hospital care.
- Testing ways to improve recovery after digestive cancer surgery
- Comparing strategies for labor induction and obstetric management
- Evaluating better approaches to anesthesia and postoperative comfort in critical care
Overall, the site combines procedural research with broader diagnostic and therapeutic studies to support better care across complex hospital settings.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 34 therapeutic areas and 15 of 610 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 567 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 132 by active trials.
lock +131 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +80 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Regional D'Angers
lock Showing 1 of 494 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21197) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 610 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 30 | Unknown | 2010-03-18 | 2026-02-18 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.